The Indian pharmaceutical distribution industry has a growth rate of 12-15% CAGR until 2030. Speciality Medicines Ltd, a pharmaceutical marketer since 2021, is an Ahmedabad-based company that specializes in high-cost oral/injectable formulations to treat chronic complicated disorders in the domestic as well as international markets.
Speciality Medicines Ltd has an efficient supply chain with a portfolio of 500+ formulations. It offers a wide range of specialty medicines. It has a good outreach through its network of hospitals, pharmacies, and distributors. It has export potential to regulated markets as well as an R&D center setup.
Speciality Medicines Ltd has shown good growth in FY25. The company has a revenue of ₹27.66 Cr (FY24). The company has shown a PAT of ₹4.57 Cr along with good margins. The company has an asset size of ₹23.43 Cr. The company has planned a BSE SME IPO of 23.50 lakh equity shares of face value of ₹10 each at an issue price of ₹117-124 per share (lot size of 1,000 shares). The company has issued fresh equity shares of ₹27.28 Cr, entirely a fresh issue.
Speciality Medicines Limited IPO Details:
Speciality Medicines Limited Issue Management:
Unicorn Capital Services Pvt Ltd acts as the book-running lead manager for Speciality Medicines Limited SME IPO, managing underwriting and compliance.
Speciality Medicines Limited IPO RTA (Registrar) Details:
Skyline Financial Services Pvt.Ltd. handles allotment, refunds, and demat credits—contact at 02228511022 or ipo@skylinerta.com.
Speciality Medicines Limited IPO Allotment Status:
To check your IPO allotment status:
Visit the Skyline Financial Services Pvt.Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Action Links:
To apply for Speciality Medicines Limited IPO, open a demat account here
Speciality Medicines Limited IPO Subscription Status: Check live subscription here
Speciality Medicines Limited IPO GMP Update: Check latest grey market premium here
Speciality Medicines Ltd, incorporated in the year 2021 in Ahmedabad, is involved in the business of marketing and distribution of high-margin specialty formulations for complex chronic therapies, with a portfolio of 500+ formulations in the oncology, cardiology, diabetology, and neurology segments.
Speciality Medicines Ltd delivered strong financial performance in the current financial year FY25 with revenue of ₹27.66 Cr (on a base of FY24) and PAT of ₹4.57 Cr with a healthy PAT margin of 16.5%. The firm maintains a healthy ROCE of 28%. The firm supplies its products to 200+ hospitals with repeat order patterns through its existing distributors, targeting regulated export markets.
IPO details: ₹29.09 Cr BSE SME IPO of Speciality Medicines Ltd @ ₹10 FV, entirely a fresh issue, with 23.50 lakh shares on offer @ ₹117-124 price band in lots of 1,000 shares ≈ ₹1.24 lakh per lot. Issue opening on March 24-26, 2026, allotment March 30, BSE SME listing April 2.
Speciality Medicines Limited IPO is ₹29.09 Cr total (fresh issue only).
Speciality Medicines Limited IPO proceeds will be deployed towards the following objectives:
Speciality Medicines Limited Ltd Mainboard IPO reserves 23.50 lakh shares per SEBI SME norms.
The Anchor bidding starts on March 23, 2026 (~28% QIB).
Lock-in: 50% for 30 days, 50% for 90 days per SEBI norms. as per SEBI SME guidelines.
The anchor allocation document filed right before issue opens will list specific anchor investor names via registrar Skyline Financial Services Pvt.Ltd.
According to RHP reports, Speciality Medicines Ltd posted solid FY25 financials. Revenue reached ₹27.66 Cr with healthy growth trajectory, PAT stood at ₹4.57 Cr (16.5% margin), ROE strong at ~28%, ROCE healthy, EBITDA supportive of margins. Growth fueled by specialty drug portfolio expansion, chronic therapy prescriptions, hospital/pharmacy network penetration.
The important risks and strengths of Speciality Medicines Limited IPO are mentioned below:
Strengths:
High-margin specialty pharma segment with a PAT margin of 16.5%. The focus is on chronic therapies with recurring prescriptions.
500+ formulations in oncology, cardiology, diabetes, and neuroscience reduce dependency on a single drug, while established distributors ensure market penetration.
Export opportunities in regulated markets, coupled with investment in the R&D center (₹8 Cr allocated in the IPO), help build the pipeline of products with premium pricing.
Asset-light distribution with working capital funding (₹15 Cr allocated) allows for scalability with minimal capex requirements.
Risks
Record against short track record in short track format incorporated in 2021 vs established pharma marketers; execution risk in R&D center and export expansion.
Regulatory dependence in approvals for specialty drugs; pressure on prices due to government tenders and NLEM inclusion in chronic formulations.
Risks in receivables are a normal part of pharma distribution business, even with high margins; concentration risk in clients from institutional buyers and hospitals.
Competition from larger players like TTK and Medplus in the specialty distribution segment.
RHPs reflect well for Speciality Medicines Limited’s FY25 numbers with Revenue ₹27.66 Cr (robust growth track), PAT ₹4.57 Cr (16.5% margin), RoNW high, and P/E ~25-30x (FY25 EPS estimate ₹19.45). This is relatively lower than its peers HCG Lifesciences’ 42x and Axishil’s 28x.
Speciality Medicines Limited’s business in specialty formulations in oncology, cardiology, diabetology, and neurology has a footprint in 200+ hospitals/pharmacies with recurring chronic prescriptions and scope for exports to regulated markets.
The company’s ₹29.09 Cr BSE SME IPO comprises 23.50 lakh shares at ₹124, the upper end of the price band, with MCap estimating ₹291 Cr at 10.5x sales and 25x earnings’ per share. Its high margins, R&D expansion, asset-light business outweigh low operating history, receivables risk for listing gains.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is for informative purposes and not investment advice.
Action Links:
To apply for Speciality Medicines Limited IPO, open a demat account here
Speciality Medicines Limited IPO Subscription Status: Check live subscription here
Speciality Medicines Limited IPO GMP Update: Check latest grey market premium here
1. What is the Speciality Medicines Limited IPO open and close date?
The Speciality Medicines Ltd BSE SME IPO opens March 24, closes March 26, 2026; allotment March 30, BSE SME listing April 2.
Track Speciality Medicines Limited IPO subscription status live here from Finnpick.
2. What is the Speciality Medicines Limited IPO price band and lot size?
The IPO price band ₹117-124 per share (FV ₹10), lot size 1,000 shares; retail minimum ₹1.24 lakh (upper band).
3. What is Speciality Medicines Limited IPO total size?
The Speciality Medicines Limited IPO size is ₹29.09 Cr fresh issue only (23.50 lakh shares), no OFS; book-built SME IPO managed by Choice Broking.
4. How to apply for the Speciality Medicines Limited IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or ASBA by Mar 30, 4 PM. Monitor Speciality Medicines Limited IPO subscription tracker here.
5. How to check Speciality Medicines Limited IPO Allotment Status?
The allotment date is on Mar 30th and can be checked on Skyline Financial Services Pvt.Ltd. portal RTA portal using PAN/DP ID.
6. What is Speciality Medicines Limited IPO GMP today and subscription status?
Current Grey Market Premium (GMP) stands at ₹0 as of March 17, indicating listing at the price range of ₹124 —check daily updates of Speciality Medicines Limited IPO GMP trends here and live subscription status here from Mar 24th opening only on Finnpick.
7. What does Speciality Medicines Limited specialize in?
Speciality Medicines Limited specializes in high-margin specialty formulations for chronic conditions—oncology, cardiology, diabetology, neurology; 500+ formulations across hospitals/pharmacies.
8. When is the Speciality Medicines Limited IPO listing date?
The Speciality Medicines Limited Ltd IPO lists on April 02nd, 2026 on BSE SME (~T+1 post-allotment Mar 30).
9. What are the Speciality Medicines Limited IPO proceeds utilization details?
The Speciality Medicines IPO fresh issue proceeds: ₹15 Cr working capital, ₹8 Cr R&D center, ₹3.5 Cr export expansion, ₹2.59 Cr general purposes.
